Incannex Healthcare (IXHL) Stock: Buy, Sell, or Hold?
IXHL - Incannex Healthcare Limited American Depositary Shares
$2.64
0.04 (1.54%)
▲
5d:
-6.38%
30d:
-22.35%
90d:
-11.56%
HOLD
MODERATE Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 13, 2026
19d
Get Alerted When IXHL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: IXHL shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: IXHL shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: IXHL is currently trading at $2.64, which is considered oversold relative to its 30-day fair value range of $2.84 to $3.46. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.1) compared to its historical average (3.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, IXHL is in a uptrend. Immediate support is located at $2.55, while resistance sits at $3.10.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $18.84 (+613.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IXHL is in a uptrend. Immediate support is located at $2.55, while resistance sits at $3.10.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $18.84 (+613.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.84 -
$3.46
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 613.5% below Wall St target ($18.84)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- NEUTRAL: Bottoming setup forming (50/100) — watch for confirmation
- CAUTION: 5-day price weakness (-6.4%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$2.84 -
$3.46
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.55
Resistance Level
$3.10
Current Trend
Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.10
Wall Street Target
$18.84
(+613.5%)
Revenue Growth (YoY)
-100.0%
PE vs Historical
-1.1 vs 3.7
CHEAP
Share & Embed Analysis
Last updated: October 24, 2026 5:39 AM ET
Data refreshes hourly during market hours. Next update: 6:39 AM
Data refreshes hourly during market hours. Next update: 6:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IXHL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 56 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 47 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 38 SELL |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$43 | 54 HOLD |
